Rasagiline
- Generic Name
- Rasagiline
- Brand Names
- Azilect, Rasagiline Mylan, Rasagiline ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13N
- CAS Number
- 136236-51-6
- Unique Ingredient Identifier
- 003N66TS6T
- Background
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
- Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
- Associated Conditions
- Parkinson's Disease (PD)
- Associated Therapies
- -
Long-term Use of CCB and Breast Cancer Risk
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Curtin University
- Target Recruit Count
- 68500
- Registration Number
- NCT05972785
- Locations
- 🇦🇺
Curtin university, Bentley, Western Australia, Australia
Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2022-11-10
- Target Recruit Count
- 732
- Registration Number
- NCT05611372
Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
- First Posted Date
- 2018-11-01
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1021
- Registration Number
- NCT03727139
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
Image Parkinson's Disease Progression Study
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 96
- Registration Number
- NCT02789020
- Locations
- 🇺🇸
Laboratory for Rehabilitation Neuroscience, Gainesville, Florida, United States
Rasagiline Rescue in Alzheimer's Disease Clinical Trial
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT02359552
- Locations
- 🇺🇸
Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States
🇺🇸Cleveland Clinic Lakewood Hospital, Lakewood, Ohio, United States
🇺🇸Cleveland Clinic Main Campus, Cleveland, Ohio, United States
Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 45
- Registration Number
- NCT02278588
- Locations
- 🇺🇸
University at Buffalo, Buffalo, New York, United States
Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 23
- Registration Number
- NCT02068625
- Locations
- 🇨🇭
Department of Ophthalmology, Bern University Hospital, Bern, Switzerland
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01879748
- Locations
- 🇺🇸
Teva Investigational Site 10738, Glendale, California, United States
Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 252
- Registration Number
- NCT01879241
- Locations
- 🇩🇪
Department of Neurology, Universty of Bonn, Bonn, Nordrhrein-Westfalen, Germany
🇩🇪Department of Neurology, TU Dresden, Dresden, Sachsen, Germany
🇩🇪Department of Neurology, University of Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Richard Barohn, MD
- Target Recruit Count
- 80
- Registration Number
- NCT01786603
- Locations
- 🇺🇸
St. Louis University, Saint Louis, Missouri, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.